Society of Urologic Oncology Clinical Trials Consortium

Nonprofit profile at a glance

EIN
262943602
IRS 990 coverage
2012–2024
Forms available
Form 990 2024, Form 990-EZ 2015
Location
Schaumburg, IL, USA
Phone
8475177225
Rating
73
Verdict
SUPPORTED
Rating confidence
Moderate
Sector
Cancer Research

Official website

Reported finances

Revenue
$684,500
Expenses
$313,029
Assets
$1,810,558
Liabilities
$82,741

Source: IRS Form 990. Selected filing: tax year 2024. Amounts in USD.

Leadership & pay

10 people listed

Executive titles in this filing

  • Viraj A Master MD PhD FACS (President)
  • Gennady Bratslavsky MD (PAST PRESIDENT)

People named in this filing

  • Viraj A Master MD PhD FACS (President)
  • Brian Matthew Shuch MD (Treasurer)
  • Gennady Bratslavsky MD (PAST PRESIDENT)

Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.

Source: IRS Form 990. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

The society is a national alliance of leading academic and community based uro-oncologists committed to the following - to further urology research and pharmaceutical trials, - to offer & provide for the best possible approach to disease education and management providing for better patient outcomes, - to provide education for the profession to further the learnings conducted through the profession, - and to allow clinicians to be aware of existing research, which advances further clinical education and hypotheses.

What it reported doing in 2024

The consortium assists doctors and hospitals conducting clinical trials with expedited concept and protocol review, standardized protocol and contract language, and centralized data management to help test needed therapies more rapidly the suo-ctc directs revenues generated from sponsor agreements to fund the collective academic, research, corporate and administrative objectives of the consortium in return the suo-ctc offers a variety of value-added services which are of shared benefit to the uro-oncology community, pharmaceutical industry both locally and abroad.

Operating model

Revenue model
Earned-program. 100% of the money available for current operations came from fees and other program revenue.
Distribution model
Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.

The verdict

SUPPORTED - The filed numbers largely add up and most voting board members are independent. A relatively small share of available resources goes toward mission work and some filing-based governance responses are negative or unanswered.

Rating breakdown

  • Financial Efficiency: 48
  • Transparency & Controls: 90
  • Accountability: 88
  • Sustainability: 85
  • Growth: 100

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: 37%; rating input score 37
  • Program expense ratio: 80.9%; rating input score 81
  • Fundraising efficiency: Limited

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
  • Pay-setting controls: Limited
  • Foreign activity oversight: Limited
  • Grant itemization coverage: Limited
  • Major donor itemization: Limited
  • Related-party transparency: Limited

Accountability

  • Independent voting board: 100%; rating input score 100; 63rd percentile among comparable filings
  • Governance controls: 5 of 7 controls in place; rating input score 71
    • Conflict-of-interest policy: Pass
    • Whistleblower policy: Fail
    • Document-retention policy: Fail
    • CEO compensation review process: NotApplicable
    • Other executive compensation review process: NotApplicable
    • Form 990 shared with the board: Pass
    • Board meeting minutes documented: Pass
    • Audit committee oversight: Pass
    • Independent financial-statement audit: Pass

Sustainability

  • Operating margin: 54.3%; rating input score 93; 93rd percentile among comparable filings
  • Total-asset coverage ratio: 5.78; rating input score 86; 86th percentile among comparable filings
  • Liabilities to assets ratio: 0.05; rating input score 53; 53rd percentile among comparable filings
  • Officer compensation ratio: 0%; rating input score 81; 81st percentile among comparable filings

Growth

  • Program expense growth: 10% per year; rating input score 100; 63rd percentile among comparable filings
  • Revenue growth: 11.1% per year; rating input score 100; 70th percentile among comparable filings
  • Asset growth: 21.3% per year; rating input score 100; 83rd percentile among comparable filings

Details

  • Where the money goes: 37% of revenue deployed · 80.9% of spending went to programs
  • Governance: 9 of 9 board members independent · 5 of 7 filing controls reported
  • Programs: 1 filed program accomplishment · $253K in reported program spending
  • Leadership: top reported pay $0 · 10 people listed
  • Highest-paid contractors: 1 contractor listed · $223K reported
  • Consistency: 20 of 20 current checks pass
  • Schedules: 3 filed schedules
  • Filing history: 10 filing years from 2012 to 2024
  • Contacts: How to reach this organization
  • Money network: 1 filed money-flow record
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • Moderate — Financial Efficiency: Mission deployment rate scored 37/100.
  • Review — Accountability: Governance controls: 2 of 7 not reported.
  • Review — Sustainability: Liabilities to assets ratio scored 53/100.